REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Rhea-AI Summary
Revelation Biosciences (NASDAQ:REVB) will participate in a fireside chat at the 38th Annual Roth Conference on March 24, 2026 at 2:00 p.m. PT in Dana Point, CA.
The event will be webcast live and later archived in the Investors section of Revelation Biosciences' website at www.RevBiosciences.com.
Positive
- None.
Negative
- None.
News Market Reaction – REVB
On the day this news was published, REVB declined 8.20%, reflecting a notable negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $379K from the company's valuation, bringing the market cap to $4M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
REVB is up 2.52% with subdued volume, while peers are mixed: ELAB and QLGN show gains of 9.38% and 7.72%, whereas ENTO, GLTO, and SLXN post declines between -0.21% and -5.68%. Momentum scanner flags ELAB and SLXN with moves of 18.50% and 4.72% up, indicating stock-specific moves rather than a unified biotech swing.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 19 | Conference participation | Neutral | -1.6% | Announcement of Roth Conference attendance and fireside chat scheduling. |
| Feb 26 | Earnings and update | Positive | -0.8% | Reported FY 2025 results, cash of $10.7M, Gemini progress and runway. |
| Jan 26 | Reverse stock split | Negative | -14.8% | 1-for-4 reverse split to address Nasdaq minimum bid requirement. |
| Jan 23 | Warrant inducement | Negative | -24.4% | Reduced-price warrant exercise and issuance of new Class J warrants. |
| Jan 21 | Regulatory pathway | Positive | -10.1% | FDA agreement on single adaptive Phase 2/3 Gemini AKI study of ~300 patients. |
Positive clinical and financing news has previously seen negative price reactions, while structurally dilutive events also aligned with sell-offs.
Over the last few months, REVB has reported several key events, including an FDA-agreed single adaptive Phase 2/3 Gemini study for AKI on Jan 21, 2026, a warrant inducement generating roughly $11 million, and a 1-for-4 reverse split effective Jan 28, 2026. Earnings on Feb 26, 2026 highlighted $10.7M year-end cash and Gemini progress. A prior Roth Conference participation announcement on Mar 19, 2026 preceded this reminder, framing today’s news as incremental rather than a new catalyst.
Regulatory & Risk Context
An amended Form S-3/A filed on Sep 29, 2025 registers common shares issuable upon exercise of Class I warrants at $2.20 per share. While the company is not selling shares directly under this prospectus, it may receive up to $28,743,000 in gross proceeds if all registered warrants are exercised for cash, providing a potential funding source linked to warrant exercises.
Market Pulse Summary
The stock moved -8.2% in the session following this news. A negative reaction despite this reminder of a Roth Conference fireside chat would fit a pattern where REVB has often traded lower around news, including reverse split and warrant inducement disclosures. With shares at $1.22, far below the 52-week high of $44.7699 and under the 200-day MA, sentiment has been fragile. Existing warrant structures and prior financing steps detailed in recent filings could also weigh on perceptions during periods of weakness.
AI-generated analysis. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced a reminder of its participation in a fireside chat on Tuesday, March 24, 2026, at 2:00 p.m. PT, as part of the 38th Annual Roth Conference, in Dana Point, CA.
The fireside chat will be webcast live here and available on our Investors section of the Revelation Biosciences website, www.RevBiosciences.com, after the meeting.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment of chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.
For more information, please visit www.RevBiosciences.com.
Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
SOURCE: Revelation Biosciences Inc.
View the original press release on ACCESS Newswire
FAQ
When is Revelation Biosciences (REVB) presenting at the Roth Conference?
How can investors watch the REVB Roth Conference fireside chat?
What topics will Revelation Biosciences (REVB) cover in the March 24, 2026 fireside chat?
Will the Revelation Biosciences (REVB) fireside chat be available after the March 24 event?
Where is the 38th Annual Roth Conference, where REVB will speak, being held?
